Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Growth Metrics

Hypha Labs (FUNI) Divestments (2022 - 2023)

Hypha Labs filings provide 3 years of Divestments readings, the most recent being -$11667.0 for Q4 2023.

On a quarterly basis, Divestments fell 337.62% to -$11667.0 in Q4 2023 year-over-year; TTM through Jun 2024 was -$14361.0, a 36.03% increase, with the full-year FY2023 number at -$11667.0, up 34.17% from a year prior.
Divestments hit -$11667.0 in Q4 2023 for Hypha Labs, down from -$2694.0 in the prior quarter.
In the past five years, Divestments ranged from a high of -$1021.0 in Q1 2023 to a low of -$13476.0 in Q3 2022.